Citations

Citations to this article as recorded by  

• Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond
  Thomas Grewal, Christa Buechler
  International Journal of Molecular Sciences.2022; 23(3): 1070.     CrossRef
• Insight into the Evolving Role of PCSK9
  Mateusz Maligłówka, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Łukasz Bułdak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Jakub Bułdak, Bogusław Okopień
  Metabolites.2022; 12(3): 256.     CrossRef
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosis
  Susanne Feder, Reiner Wiest, Thomas S. Weiss, Charalampos Aslanidis, Doris Schacherer, Sabrina Krautbauer, Gerhard Liebisch, Christa Buechler
  Lipids in Health and Disease.2021;[Epub]     CrossRef

Citations

Citations to this article as recorded by  

• Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial
  Ghina Tsurayya, Cut Alifiya Nazhifah, Muhammad Rahmat Pirwanja, Putri Oktaviani Zulfa, Muhammad Raihan Ramadhan Tatroman, Fajar Fakri, Muhammad Iqhrammullah
  Children.2024; 11(2): 227.     CrossRef
• Efficacy, safety, and patient satisfaction of norditropin and sogroya in patients with growth hormone deficiency: a systematic review and meta-analysis of randomized controlled trials
  Obieda Altobaishat, Mohamed Abouzid, Mostafa Hossam El Din Moawad, Abdulrahman Sharaf, Yazan Al-Ajlouni, Tungki Pratama Umar, Abdallah Bani-salameh, Mohammad Tanashat, Omar Abdullah Bataineh, Abdulqadir J. Nashwan
  Endocrine.2024;[Epub]     CrossRef
• Evaluation of Adult Height in Patients with Non-Permanent Idiopathic GH Deficiency
  Agnese Murianni, Anna Lussu, Chiara Guzzetti, Anastasia Ibba, Letizia Casula, Mariacarolina Salerno, Marco Cappa, Sandro Loche
  Endocrines.2023; 4(1): 169.     CrossRef
• The effect of hypothalamic involvement and growth hormone treatment on cardiovascular risk factors during the transition period in patients with childhood-onset craniopharyngioma
  Sang Hee Park, Yun Jeong Lee, Jung-Eun Cheon, Choong Ho Shin, Hae Woon Jung, Young Ah Lee
  Annals of Pediatric Endocrinology & Metabolism.2023; 28(2): 107.     CrossRef
• Continuous Glucose Monitoring: A Possible Aid for Detecting Hypoglycemic Events during Insulin Tolerance Tests
  Soo Yeun Sim, Moon Bae Ahn
  Sensors.2023; 23(15): 6892.     CrossRef
• The risk patients with AGHD have of developing CVD
  Eisha Javed, Maha Zehra, Naz Elahi
  International Journal of Cardiology Cardiovascular Risk and Prevention.2023; 19: 200221.     CrossRef
• Diagnosis of GH Deficiency Without GH Stimulation Tests
  Anastasia Ibba, Sandro Loche
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency
  Yun Jeong Lee, Yunha Choi, Han-Wook Yoo, Young Ah Lee, Choong Ho Shin, Han Saem Choi, Ho-Seong Kim, Jae Hyun Kim, Jung Eun Moon, Cheol Woo Ko, Moon Bae Ahn, Byung-Kyu Suh, Jin-Ho Choi
  Endocrinology and Metabolism.2022; 37(2): 359.     CrossRef
• A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI
  Taeyoun Lee, Kyungchul Song, Beomseok Sohn, Jihwan Eom, Sung Soo Ahn, Ho-Seong Kim, Seung-Koo Lee
  Yonsei Medical Journal.2022; 63(9): 856.     CrossRef
• Phenotypic spectrum of patients with mutations in CHD7: clinical implications of endocrinological findings
  Ja Hye Kim, Yunha Choi, Soojin Hwang, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi
  Endocrine Connections.2022;[Epub]     CrossRef
• Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
  Hyemi Kwon, Eun Roh, Chang Ho Ahn, Hee Kyung Kim, Cheol Ryong Ku, Kyong Yeun Jung, Ju Hee Lee, Eun Heui Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Jun Sung Moon, Jin Hwa Kim, Mi-kyung Kim
  Endocrinology and Metabolism.2022; 37(6): 839.     CrossRef
• Laron syndrome: clinic, diagnostics (а clinical case)
  P.M. Lіashuk, R.P. Lіashuk, N.I. Stankova, M.B. Kudina
  INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2022; 18(3): 193.     CrossRef
• Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force
  Eu Jeong Ku, Kyoung Jin Kim, Jung Hee Kim, Mi Kyung Kim, Chang Ho Ahn, Kyung Ae Lee, Seung Hun Lee, You-Bin Lee, Kyeong Hye Park, Yun Mi Choi, Namki Hong, A Ram Hong, Sang-Wook Kang, Byung Kwan Park, Moon-Woo Seong, Myungshin Kim, Kyeong Cheon Jung, Chan
  Endocrinology and Metabolism.2021; 36(2): 322.     CrossRef
• Asian Conference on Tumor Ablation Guidelines for Adrenal Tumor Ablation
  Byung Kwan Park, Masashi Fujimori, Shu-Huei Shen, Uei Pua
  Endocrinology and Metabolism.2021; 36(3): 553.     CrossRef
• Asian Conference on Tumor Ablation guidelines for renal cell carcinoma
  Byung Kwan Park, Shu-Huei Shen, Masashi Fujimori, Yi Wang
  Investigative and Clinical Urology.2021; 62(4): 378.     CrossRef
• Diagnosis and Treatment of Adult Growth Hormone Deficiency
  Jung Hee Kim
  The Korean Journal of Medicine.2021; 96(5): 400.     CrossRef

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

Citations

Citations to this article as recorded by  

• Hydrogel-fiber-mesh-based 3D cell cultures: A new method for studying pituitary tumors
  Wooju Jeong, Sungrok Wang, Yumin Kim, Soohyun Lee, Minhu Huang, Jaeil Park, Myung-Han Yoon, Chang-Myung Oh, Cheol Ryong Ku
  Smart Materials in Medicine.2024;[Epub]     CrossRef
• Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association
  A Ram Hong, Ho-Cheol Kang
  Endocrinology and Metabolism.2023; 38(2): 175.     CrossRef
• Growth Hormone Excess: Implications and Management
  Suneela Dhaneshwar, Shrishti Shandily, Vatsalya Tiwari
  Endocrine, Metabolic & Immune Disorders - Drug Targets.2023; 23(6): 748.     CrossRef
• Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
  Montserrat Marques-Pamies, Joan Gil, Elena Valassi, Marta Hernández, Betina Biagetti, Olga Giménez-Palop, Silvia Martínez, Cristina Carrato, Laura Pons, Rocío Villar-Taibo, Marta Araujo-Castro, Concepción Blanco, Inmaculada Simón, Andreu Simó-Servat, Gemm
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Evaluation and Management of Bone Health in Patients with Thyroid Diseases: a Position Statement from the Korean Thyroid Association
  A Ram Hong, Hwa Young Ahn, Bu Kyung Kim, Seong Hee Ahn, So Young Park, Min-Hee Kim, Jeongmin Lee, Sun Wook Cho, Ho-Cheol Kang
  International Journal of Thyroidology.2022; 15(1): 1.     CrossRef
• Octreotide in the treatment of acromegaly – the possibilities of high-dose therapy
  I. A. Ilovayskaya
  Meditsinskiy sovet = Medical Council.2022; (10): 148.     CrossRef
• Approach of Acromegaly during Pregnancy
  Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascălu, Tiberiu Tircă, Jaqueline Abdul-Razzak, Mihaela Jana Țuculină
  Diagnostics.2022; 12(11): 2669.     CrossRef
• Left to themselves: Time to target chronic pain in childhood rare diseases
  Christine B. Sieberg, Alyssa Lebel, Erin Silliman, Scott Holmes, David Borsook, Igor Elman
  Neuroscience & Biobehavioral Reviews.2021; 126: 276.     CrossRef
• Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide
  Jacob Luty, LesleAnn Hayward, Melanie Jackson, P Barton Duell
  BMJ Case Reports.2021; 14(8): e243900.     CrossRef
• Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?
  Cheol Ryong Ku, Vladimir Melnikov, Zhaoyun Zhang, Eun Jig Lee
  Endocrinology and Metabolism.2020; 35(2): 206.     CrossRef
• Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
  Sang Ouk Chin, Cheol Ryong Ku, Byung Joon Kim, Sung-Woon Kim, Kyeong Hye Park, Kee Ho Song, Seungjoon Oh, Hyun Koo Yoon, Eun Jig Lee, Jung Min Lee, Jung Soo Lim, Jung Hee Kim, Kwang Joon Kim, Heung Yong Jin, Dae Jung Kim, Kyung Ae Lee, Seong-Su Moon, Dong
  The Korean Journal of Medicine.2019; 94(6): 485.     CrossRef